title: Effects of fibroblast-mediated interleukin 3 and interleukin 6 gene therapy on hematopoiesis in mice treated with 5-fluorouracil.
abstract: Fibroblast-mediated cytokine gene therapy has proven to be a promising strategy for restoring hematopoiesis following repeated chemotherapy. Interleukin 3 (IL-3) and interleukin 6 (IL-6) can synergistically promote the recovery of hematopoiesis following chemotherapy. In this investigation, combined use of fibroblast-mediated IL-3 and IL-6 gene therapy was tested for hematopoietic effects on mice with or without 5-fluorouracil administration. The results demonstrated that combined therapy with IL-3 gene-modified NIH3T3 cell (NIH3T3-IL-3) and IL-6 gene-modified fibroblast NIH3T3 cell (NIH3T3-IL-6) implantation achieves obvious stimulation of hematopoiesis in normal mice and accelerates recovery of hematopoiesis. In normal mice the quantities of platelets, neutrophils, and total white blood cells in peripheral blood increased significantly after the combined implantation of NIH3T3-IL-3 and NIH3T3-IL-6 cells. The numbers of colony-forming unit (CFU) granulocyte/macrophage (CFU-GM) and CFU megakaryocyte (CFU-MK) formed by stem cells in bone marrow was significantly higher after the combined implantation of NIH3T3-IL-3 and NIH3T3-IL-6 cells than after the implantation of NIH3T3-IL-3 alone, NIH3T3-IL-6 alone, or neomycin gene-modified NIH3T3 cells. In hematopoiesis-depressed mice induced by preinjection with 5-fluorouracil at the dose of 150 mg/kg before cell implantation, the platelets, neutrophils, and white blood cells showed accelerated recovery, and the numbers of CFU-GM and CFU-MK formed by bone marrow cells were also markedly higher after the combined implantation of NIH3T3-IL-3 and NIH3T3-IL-6 cells than in control groups. Our data show that combined use of fibroblast-mediated IL-3 and IL-6 gene therapy may be of clinical relevance for the recovery of hematopoietic depression for patients after chemotherapy.
authors.affiliation: Department of Immunology, Second Military Medical University, Shanghai, P.R. China.
authors.forename: X
authors.initials: X
authors.lastname: Cao
authors.forename: D W
authors.initials: DW
authors.lastname: Ju
authors.forename: R
authors.initials: R
authors.lastname: Cai
authors.forename: Q
authors.initials: Q
authors.lastname: Tao
authors.forename: Y
authors.initials: Y
authors.lastname: Yu
authors.forename: J
authors.initials: J
authors.lastname: Wang
mesh_terms: D016475:3T3 Cells; D000818:Animals; D001854:Bone Marrow Cells; D005472:Fluorouracil / Q000494:pharmacology*; D015316:Genetic Therapy; D006098:Granulocytes; D006410:Hematopoiesis; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007377:Interleukin-3 / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology*; D007962:Leukocytes; D008264:Macrophages; D008297:Male; D008533:Megakaryocytes; D051379:Mice; D008807:Mice, Inbred BALB C; D010976:Platelet Count
chemical_list: D007166:Immunosuppressive Agents; D007377:Interleukin-3; D015850:Interleukin-6; D005472:Fluorouracil